Efebera, Y.; Suman, V.; Dinner, S.; O’Donnell, T.; Rosko, A.; Mckay, J.; Barth, P.; Hagen, P.; Usmani, S.; Richardson, P.;
et al. Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15). Cancers 2025, 17, 2433.
https://doi.org/10.3390/cancers17152433
AMA Style
Efebera Y, Suman V, Dinner S, O’Donnell T, Rosko A, Mckay J, Barth P, Hagen P, Usmani S, Richardson P,
et al. Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15). Cancers. 2025; 17(15):2433.
https://doi.org/10.3390/cancers17152433
Chicago/Turabian Style
Efebera, Yvonne, Vera Suman, Shira Dinner, Taylor O’Donnell, Ashley Rosko, John Mckay, Peter Barth, Patrick Hagen, Saad Usmani, Paul Richardson,
and et al. 2025. "Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15)" Cancers 17, no. 15: 2433.
https://doi.org/10.3390/cancers17152433
APA Style
Efebera, Y., Suman, V., Dinner, S., O’Donnell, T., Rosko, A., Mckay, J., Barth, P., Hagen, P., Usmani, S., Richardson, P., & Laubach, J.
(2025). Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15). Cancers, 17(15), 2433.
https://doi.org/10.3390/cancers17152433
